Vervaat Fabienne E, Bouwmeester Sjoerd, Vlaar Pieter-Jan
Department of Cardiology, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands.
Eur Heart J Case Rep. 2021 Jan 11;5(1):ytaa426. doi: 10.1093/ehjcr/ytaa426. eCollection 2021 Jan.
Cardiac amyloidosis is an important cause for heart failure with preserved ejection fraction. It is often under diagnosed due to the fact that clinicians do not always recognize the specific diagnostic findings associated with this disease, also leading to the wrong diagnosis. When left untreated further irreversible organ dysfunction occurs, with high morbidity and mortality rates.
A 71-year-old patient presented with progressive exertional dyspnoea and angina pectoris at the outpatient clinic. Medical history noted a percutaneous coronary intervention of the right coronary artery due to stable angina pectoris. The electrocardiogram showed low voltage in the limb leads and pseudo-infarct pattern in the precordial leads. Echocardiographic findings included left and right ventricular hypertrophy, decreased left ventricular systolic function, restrictive diastolic function, and 'relative' apical sparing of the left ventricle. This led to the suspicion of cardiac amyloidosis, which was confirmed with a positive bone scintigraphy using Technecium-DPD and the absence of monoclonal proteins. Treatment with Tafamidis was initiated.
Electrocardiographic findings suggestive of cardiac amyloidosis are low voltage in the limb leads and/or a pseudo-infarct pattern in the precordial leads. Important echocardiographic findings are left and right ventricular hypertrophy, restrictive diastolic function, 'relative' apical sparing of the left ventricle and impaired left atrial strain. The next step in confirming the diagnosis is Technecium PYP/DPD/HMDP bone scintigraphy and testing for monoclonal proteins. The diagnosis ATTR amyloidosis is confirmed by the combination of positive bone scintigraphy (Perugini Grade 2 or 3) and the absence of monoclonal proteins, without the necessity of performing an endomyocardial biopsy.
心脏淀粉样变性是射血分数保留的心力衰竭的重要原因。由于临床医生并不总是认识到与该疾病相关的特定诊断结果,该病常常诊断不足,这也会导致误诊。若不进行治疗,会进一步出现不可逆的器官功能障碍,发病率和死亡率都很高。
一名71岁患者在门诊表现为进行性劳力性呼吸困难和心绞痛。病史显示因稳定型心绞痛接受过右冠状动脉的经皮冠状动脉介入治疗。心电图显示肢体导联低电压,胸前导联出现假性梗死图形。超声心动图检查结果包括左、右心室肥厚,左心室收缩功能降低,舒张功能受限,以及左心室“相对”的心尖部 spared。这引发了对心脏淀粉样变性的怀疑,经使用锝 - DPD进行的骨闪烁显像呈阳性且无单克隆蛋白而得以确诊。开始使用塔非酰胺进行治疗。
提示心脏淀粉样变性的心电图表现为肢体导联低电压和/或胸前导联假性梗死图形。重要的超声心动图表现为左、右心室肥厚,舒张功能受限,左心室“相对”的心尖部 spared以及左心房应变受损。确诊的下一步是进行锝PYP/DPD/HMDP骨闪烁显像和单克隆蛋白检测。骨闪烁显像阳性(佩鲁吉尼2级或3级)且无单克隆蛋白,无需进行心内膜心肌活检即可确诊ATTR淀粉样变性。